Όλο το DSpace

Πλοήγηση ανά Θέμα "pravastatin"

Αποτελέσματα 1-3 από 3

    • Expert consensus on the rational clinical use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors 

      Achimastos A., Alexandrides T., Alexopoulos D., Athyros V., Bargiota A., Bilianou E., Chrysochoou C., Drogari E., Elisaf M., Ganotakis E., Goudevenos I., Ioannidis I., Kolovou G., Kotsis V., Lekakis I., Liberopoulos E., Melidonis A., Nikolaou V., Ntaios G., Papanas N., Pappas S., Pitsavos C., Rallidis L., Richter D., Skoumas I., Tentolouris N., Tousoulis D., Tselepis A., Tsioufis K., Tziakas D., Tziomalos K., Vardas P., Vlachopoulo C., Vlahakos D. (2016)
      Two proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, evolocumab and alirocumab, have recently been approved by both the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the ...

    • Marketed drugs used for the management of hypercholesterolemia as anticancer armament 

      Papanagnou P., Stivarou T., Papageorgiou I., Papadopoulos G.E., Pappas A. (2017)
      The design of novel pharmacologic agents as well as their approval for sale in markets all over the world is a tedious and pricey process. Inevitably, oncologic patients commonly experience unwanted effects of new anticancer ...

    • Statin-based therapy for primary and secondary prevention of ischemic stroke: A meta-analysis and critical overview 

      Milionis H., Ntaios G., Korompoki E., Vemmos K., Michel P. (2020)
      Background and aims: To reassess the effect of statin-based lipid-lowering therapy on ischemic stroke in primary and secondary prevention trials with regard to achieved levels of low-density lipoprotein-cholesterol in view ...